Drug Discovery to Development Innovation Forum Speakers
Chief Scientific Officer
Alan Whitmore is Chief Scientific Officer at e-Therapeutics PLC. He moved from academia into biotech 12 years ago and has worked in both drug delivery and drug discovery.
Vice President, Head of Chemistry
Dr. Stephanos Ioannidis obtained his B.Sc. at King's College London in chemistry and biochemistry before moving to Imperial College London
Javier is Chief Scientific Officer (CSO) and co-founder at ZeClinics. He is an expert in zebrafish biology and the exploitation of this animal model for drug discovery purposes.
Director of Discovery Biology & Discovery Sciences
Rob has been at AstraZeneca since 2016 where he leads the Discovery Biology department part of the Innovative Medicines organisation.
Founder & CEO
Dr. Varshney’s research and development expertise are diverse, and encompasses physiology and medicine (DVM), computational biology and machine learning/artificial intelligence (ML/AI) (PhD).
Chief Scientific Officer
InterAx Biotech AG
Dr. Waldhoer has a 25+ year experience both in academia and industry in Europe and the US, working in early R&D project management and drug discovery.
Jonathan S Mason
Senior Research Fellow
Dr Jonathan S Mason is a Senior Research Fellow at Sosei Heptares for GPCR structure-based drug design and a Scientific Advisor to several innovative biotech companies
Director of Biology
Pilar holds a PhD in Pharmacy from the Universitat de Barcelona. Supported by a Fulbright Postdoctoral Fellowship she worked at Harvard Medical School and later at Duke’s University, Durham (USA).
Sr. Vice President – Discovery Services
Kenneth holds a Ph.D. in Synthetic Organic/Organometallic Chemistry from Massachusetts Institute of Technology and has pursued his Postdoctoral study in Natural product synthesis
Vivek K Vishnudas
Sr Vice President
As Senior Vice President, Drug Discovery and Platform Sciences, Vivek Vishnudas, oversees the development of experimental therapeutics from conception and drug discovery to first-in-human studies.
Director BD&L Research Platforms
In the new Sanofi R&D organization, H. Haag is responsible for sourcing and external business within the Lead Generation department and is a member of its leadership team.
Dora Barna received her MSc degree in Chemistry in 2009, and PhD degree in Theoretical Chemistry in 2013 from the University of Szeged, Faculty of Science and Informatics, in Hungary.
Global Head of Computer-Aided Drug Discovery
José is Global Head of Computer Aided Drug Discovery (CADD), part of
Global Discovery Chemistry at the Novartis Institutes for BioMedical
VP Novel Target Biology and Genomics
Alun is currently VP Novel Target Biology and Genomics at C4X Discovery. He has over 35 years experience in pharmaceutical R&D, including drug discovery and genetics research.
Dr. Martin Akerman is a data scientist trained in biology and computer science with a PhD from Technion (Israel) and a post doctorate from Cold Spring Harbor Laboratory (CSHL).
Chief Technology Officer
Markus is a data scientist with a background functional genetic screening, engineering and bioinformatics and is leading the screening group and bioinformatics team at PhoreMost